Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with Dr. Deepa Madduri about an emerging CAR T-cell therapy for relapsed/refractory multiple
myeloma
2. Comparable outcomes with ixazomib-lenalidomide-dexamethasone in routine clinical practice compared to the
phase III TOURMALINE-MM1 trial
3. The bispecific antibody mosunetuzumab exhibits promising activity in heavily pretreated non-Hodgkin lymphoma
4. Long-term follow-up data confirms superior tumor control of more intensive chemoradiationtherapy with early-
stage, unfavorable Hodgkin’s lymphoma
5. Two years of rituximab following bendamustine-rituximab induction does not add significant benefit in patients
with Waldenström's macroglobulinemia